Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Nimbus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Anagenex and Nimbus will discover small molecule drugs for multiple challenging targets by applying Anagenex’s AI driven parallel biochemistry platform to generate experimentally measured datapoints for each of Nimbus’ nomina...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Nimbus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Catalio
Deal Size : $30.0 million
Deal Type : Series A Financing
Details : Anagenex will use its Series A funds to further expand its novel data generating platform and build a robust pipeline of programs addressing historically challenging unmet medical needs.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 08, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Catalio
Deal Size : $30.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?